c-Met/HGFR
Les inhibiteurs de c-Met/HGFR ciblent le Récepteur du Facteur de Croissance des Hépatocytes (c-Met), une tyrosine kinase impliquée dans des processus cellulaires tels que la croissance, la motilité et la morphogenèse. La signalisation de c-Met est impliquée dans la progression du cancer, la métastase et la résistance aux thérapies. Inhiber c-Met peut perturber la croissance et la propagation des tumeurs, faisant de ces inhibiteurs des outils précieux dans la recherche sur le cancer. Chez CymitQuimica, nous proposons des inhibiteurs de c-Met/HGFR pour soutenir vos recherches en oncologie, métastase et thérapies ciblées contre le cancer.
144 produits trouvés pour "c-Met/HGFR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
SRI 31215 TFA
CAS :SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.Formule :C27H34F3N5O3Degré de pureté :98.25% - 99.97%Couleur et forme :SolidMasse moléculaire :533.6Ref: TM-T5478
1mg40,00€5mg92,00€10mg128,00€25mg248,00€50mg370,00€100mg527,00€200mg713,00€1mL*10mM (DMSO)96,00€Cabozantinib
CAS :Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).
Formule :C28H24FN3O5Degré de pureté :99.68% - 99.88%Couleur et forme :SolidMasse moléculaire :501.51(Z)-Semaxinib
CAS :(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition forFormule :C15H14N2ODegré de pureté :98.82% - ≥95%Couleur et forme :SolidMasse moléculaire :238.28Ref: TM-T2496
10mg35,00€25mg52,00€50mg79,00€100mg111,00€200mg168,00€500mg330,00€1mL*10mM (DMSO)44,00€Cabozantinib hydrochloride
CAS :Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6Formule :C28H25ClFN3O5Degré de pureté :99.97%Couleur et forme :SolidMasse moléculaire :537.96Ref: TM-T5164
1mg42,00€2mg52,00€5mg65,00€10mg92,00€25mg160,00€50mg235,00€100mg330,00€200mg538,00€500mg860,00€BAY-474
CAS :BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probeFormule :C17H15N5Degré de pureté :98.98%Couleur et forme :SolidMasse moléculaire :289.33Ref: TM-T7900
1mg35,00€5mg71,00€10mg112,00€25mg203,00€50mg294,00€100mg411,00€200mg553,00€1mL*10mM (DMSO)84,00€Afatinib
CAS :Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.Formule :C24H25ClFN5O3Degré de pureté :98.56% - 99.9%Couleur et forme :Off-White SolidMasse moléculaire :485.94Ref: TM-T21312
5mg34,00€10mg49,00€25mg81,00€50mg109,00€100mg137,00€200mg168,00€500mg284,00€1mL*10mM (DMSO)50,00€Amivantamab (Anti-c-MET)
CAS :Amivantamab (JNJ-61186372) is an antibody that recognizes EGFR and MET and has anticancer and antitumor activities.Degré de pureté :97.24% (SEC-HPLC) - >95.0% (SDS-PAGE); 99.74% (SEC-HPLC)Couleur et forme :LiquidMasse moléculaire :145.88 kDaBafisontamab
CAS :Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].Couleur et forme :LiquidDavutamig
CAS :Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.Degré de pureté :98%Couleur et forme :LiquidFiclatuzumab
CAS :Ficlatuzumab is a humanized anti-HGF mAb that inhibits c-Met signaling for squamous cell carcinoma treatment.Degré de pureté :95%Couleur et forme :LiquidMasse moléculaire :145.39 kDaMAPK-IN-2
MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cellFormule :C20H11Cl2N3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :380.23BMS-754807
CAS :BMS-754807 is an oral IGF-1R/InsR inhibitor with potential anti-cancer properties.Formule :C23H24FN9ODegré de pureté :99.69% - 99.94%Couleur et forme :SolidMasse moléculaire :461.49Ref: TM-T2349
1mg50,00€2mg66,00€5mg90,00€10mg158,00€25mg310,00€50mg509,00€100mg732,00€1mL*10mM (DMSO)110,00€AMG-458
CAS :AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.Formule :C30H29N5O5Degré de pureté :99.91% - 99.98%Couleur et forme :SolidMasse moléculaire :539.58SU11274
CAS :SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.Formule :C28H30ClN5O4SDegré de pureté :98.62% - 99.53%Couleur et forme :Orange PowderMasse moléculaire :568.09Ref: TM-T6154
1mg44,00€2mg56,00€5mg92,00€10mg142,00€25mg268,00€50mg442,00€100mg652,00€1mL*10mM (DMSO)142,00€T-1840383
CAS :T-1840383 blocks VEGFR-2 and c-Met phosphorylation in endothelial and cancer cells.Formule :C30H25ClFN5O4Couleur et forme :SolidMasse moléculaire :574c-Met-IN-13
CAS :c-Met-IN-13: potent c-Met inhibitor (IC50 2.43 nM), exhibits anti-proliferative, cytotoxic effects; potential cancer therapy.Formule :C30H28F2N2O6Couleur et forme :SolidMasse moléculaire :550.55c-Met-IN-12
CAS :c-Met-IN-12: potent c-Met/AXL/Mer/TYRO3 inhibitor, IC50=10.6 nM, oral, anti-tumor, scaffold for selectivity enhancement.Formule :C34H29FN4O4Couleur et forme :SolidMasse moléculaire :576.62(R)-Afatinib
CAS :(R)-Afatinib: oral ErbB inhibitor (EGFR/HER2), IC50 ≤14 nM. For ESCC, NSCLC, gastric cancer research.Formule :C24H25ClFN5O3Couleur et forme :SolidMasse moléculaire :485.94Dalmelitinib
CAS :Dalmelitinib: oral c-Met kinase inhibitor, IC50 2.9 nM, disrupts MET, AKT, ERK in cancer cells, for NSCLC research.Formule :C22H16FN7O2SCouleur et forme :SolidMasse moléculaire :461.47MK-8033 hydrochloride
CAS :MK-8033 hydrochloride is an oral ATP-competitive c-Met/Ron inhibitor (IC50: c-Met 1nM, Ron 7nM), used for various cancers including NSCLC.Formule :C25H22ClN5O3SCouleur et forme :SolidMasse moléculaire :507.99
